AU2007269144B2 - Treatment of neurodegenerative diseases through inhibition of HSP90 - Google Patents

Treatment of neurodegenerative diseases through inhibition of HSP90 Download PDF

Info

Publication number
AU2007269144B2
AU2007269144B2 AU2007269144A AU2007269144A AU2007269144B2 AU 2007269144 B2 AU2007269144 B2 AU 2007269144B2 AU 2007269144 A AU2007269144 A AU 2007269144A AU 2007269144 A AU2007269144 A AU 2007269144A AU 2007269144 B2 AU2007269144 B2 AU 2007269144B2
Authority
AU
Australia
Prior art keywords
tau
hsp90
compound
disease
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007269144A
Other languages
English (en)
Other versions
AU2007269144A1 (en
Inventor
Gabriela Chiosis
Fei Dou
Paul Greengard
Huazhong He
Wenjie Luo
Danuta Zatorska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Memorial Sloan Kettering Cancer Center
Original Assignee
Rockefeller University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Memorial Sloan Kettering Cancer Center filed Critical Rockefeller University
Publication of AU2007269144A1 publication Critical patent/AU2007269144A1/en
Priority to AU2013205338A priority Critical patent/AU2013205338B2/en
Application granted granted Critical
Publication of AU2007269144B2 publication Critical patent/AU2007269144B2/en
Priority to AU2017200078A priority patent/AU2017200078C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007269144A 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibition of HSP90 Ceased AU2007269144B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2013205338A AU2013205338B2 (en) 2006-06-30 2013-04-11 Treatment of neurodegenerative diseases through inhibition of Hsp90
AU2017200078A AU2017200078C1 (en) 2006-06-30 2017-01-06 Treatment of neurodegenerative diseases through inhibition of Hsp90

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
US60/806,427 2006-06-30
PCT/US2007/072671 WO2008005937A2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibiton of hsp90

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013205338A Division AU2013205338B2 (en) 2006-06-30 2013-04-11 Treatment of neurodegenerative diseases through inhibition of Hsp90

Publications (2)

Publication Number Publication Date
AU2007269144A1 AU2007269144A1 (en) 2008-01-10
AU2007269144B2 true AU2007269144B2 (en) 2013-05-16

Family

ID=38895418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007269144A Ceased AU2007269144B2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibition of HSP90

Country Status (8)

Country Link
US (5) US10336757B2 (OSRAM)
EP (2) EP2034839B1 (OSRAM)
JP (5) JP5599610B2 (OSRAM)
AU (1) AU2007269144B2 (OSRAM)
CA (1) CA2656202C (OSRAM)
DK (1) DK2034839T3 (OSRAM)
ES (1) ES2645095T3 (OSRAM)
WO (1) WO2008005937A2 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2652263A1 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
EP2069324B1 (en) 2007-03-20 2013-07-31 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
AU2008322503A1 (en) * 2007-11-14 2009-05-22 Myrexis, Inc. Therapeutic compounds and their use in treating diseases and disorders
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
CA2832530C (en) * 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
CN104081203B (zh) * 2011-07-08 2018-07-31 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
EP2948447B1 (en) 2013-01-23 2016-09-21 Astrazeneca AB Chemical compounds
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3033338A4 (en) 2013-08-16 2017-06-14 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
RU2016128528A (ru) 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
JP2017505777A (ja) 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
EP3131586A4 (en) 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
DK3193840T3 (da) 2014-09-15 2021-08-16 Orphazyme As Arimoclomol-formulering
AU2015317632B2 (en) * 2014-09-17 2022-01-13 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
EA201890623A1 (ru) 2015-10-05 2018-09-28 Мемориал Слоун Кеттеринг Кэнсер Сентр Рациональная комбинированная терапия для лечения рака
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
SG10201913562VA (en) * 2017-04-24 2020-03-30 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
CA3067572A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
KR20200019220A (ko) * 2017-06-23 2020-02-21 사무스 테라퓨틱스, 인코포레이티드 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
EP4031132A4 (en) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activating pyruvate kinase r
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036075A2 (en) * 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
JP2005524661A (ja) 2002-02-28 2005-08-18 アストラゼネカ アクチボラグ ３−シクリル−５−（窒素含有５員環）メチル−オキサゾリジノン誘導体と抗菌剤としてのその使用
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20070178537A1 (en) 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
KR101617774B1 (ko) 2005-02-25 2016-05-04 에사넥스, 인코포레이티드 테트라히드로인돌론 및 테트라히드로인다졸론 유도체
US20110263693A1 (en) 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
CA2652263A1 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
WO2008013985A2 (en) 2006-07-27 2008-01-31 University Of Florida Use of heat shock activators for tissue regeneration
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008070472A2 (en) 2006-11-27 2008-06-12 University Of Maryland, Baltimore Use of plasma hsp90 related to malignancy
EP2069324B1 (en) 2007-03-20 2013-07-31 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
WO2009007399A1 (en) 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
AU2008322503A1 (en) 2007-11-14 2009-05-22 Myrexis, Inc. Therapeutic compounds and their use in treating diseases and disorders
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP3033338A4 (en) 2013-08-16 2017-06-14 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036075A2 (en) * 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules

Also Published As

Publication number Publication date
ES2645095T3 (es) 2017-12-04
US20240158397A1 (en) 2024-05-16
AU2007269144A1 (en) 2008-01-10
JP2016028063A (ja) 2016-02-25
US20230060990A1 (en) 2023-03-02
CA2656202A1 (en) 2008-01-10
JP5599610B2 (ja) 2014-10-01
DK2034839T3 (en) 2017-12-04
WO2008005937A2 (en) 2008-01-10
JP6427227B2 (ja) 2018-11-21
EP3305297A1 (en) 2018-04-11
CA2656202C (en) 2018-01-16
WO2008005937A3 (en) 2008-12-11
JP6585266B2 (ja) 2019-10-02
US12473288B2 (en) 2025-11-18
US10336757B2 (en) 2019-07-02
US20090298857A1 (en) 2009-12-03
EP2034839B1 (en) 2017-08-23
JP2013177389A (ja) 2013-09-09
JP5824698B2 (ja) 2015-11-25
JP2019038829A (ja) 2019-03-14
US20190389864A1 (en) 2019-12-26
JP2009542716A (ja) 2009-12-03
US20140378452A1 (en) 2014-12-25
JP2017214379A (ja) 2017-12-07
EP2034839A2 (en) 2009-03-18
EP2034839A4 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
US12473288B2 (en) Treatment of neurodegenerative diseases through inhibiton of Hsp90
Kaur et al. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases
CA2656413C (en) Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals
ES2897712T3 (es) Procedimientos para seleccionar inhibidores selectivos de fosfatasa y no selectivos de fosfatasa
US8357673B2 (en) 4-arylazo-3,5-diamino-pyrazole compounds and use thereof
Liu et al. Development of bisindole-substituted aminopyrazoles as novel GSK-3β inhibitors with suppressive effects against microglial inflammation and oxidative neurotoxicity
AU2017200078B2 (en) Treatment of neurodegenerative diseases through inhibition of Hsp90
HK1253803A1 (en) Treatment of neurodegenerative diseases through inhibition of hsp90
Yang et al. Alzheimer's Disease and Cancer: Common Targets
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
WO2013149976A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
EP2970118B1 (en) Compounds for the treatment of neurological disorders
EP2662081A1 (en) Therapeutic use of indole-dihydro-imidazole derivatives

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITION OF HSP90

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LUO, WENJIE; GREENGARD, PAUL; DOU, FEI; CHIOSIS, GABRIELA; HE, HUAZHONG AND ZATORSKA, DANUTA

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LUO, WENJIE; GREENGARD, PAUL; DOU, FEI; CHIOSIS, GABRIELA; HE, HUAZHONG AND ZATORSKA, DANUTA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired